Pharmacovigilance: Betamimetic drug exposure in pregnancy enhances cardiovascular disease risk of offspring

Cristina Maggioni; Germaine G Cornelissen-Guillaume; Elena V. Syutkina; Dana E Johnson; Franz Halberg

Pharmacovigilance: Betamimetic drug exposure in pregnancy enhances cardiovascular disease risk of offspring

Cristina Maggioni, Germaine G Cornelissen-Guillaume, Elena V. Syutkina, Dana E Johnson, Franz Halberg

Research output: Contribution to journal › Article › peer-review

Abstract

The circadian amplitude of neonatal blood pressure, monitored for 2 days at 30-minute intervals during the first week of life on 39 babies exposed in utero to betamimetics, was statistically significantly larger than that of the 126 unexposed babies. The respective circadian double amplitudes (± SEM) were 7.9 ± 0.8 vs. 5.6 ± 0.3 mm Hg for systolic blood pressure (P=0.005) and 5.7 ± 0.6 vs. 4.0 ± 0.2 mm Hg for diastolic blood pressure (P = 0.020). An above-threshold circadian amplitude of blood pressure being associated with an increased cardiovascular disease risk, the results, corroborated independently during adolescence, warrant caution in prescribing betamimetics to prevent premature labor.

Original language	English (US)
Pages (from-to)	102-104
Number of pages	3
Journal	Neuroendocrinology Letters
Volume	24
Issue number	SUPPL. 1
State	Published - 2003

Keywords

Betamimetics
Blood pressure
Cardiovascular disease risk
Circadian amplitude
Neonate
Offspring
Pregnancy
Premature labor

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

OpenUrl availability

Full text

Cite this

@article{459aad4e6ba045b18c92a59551a3121a,

title = "Pharmacovigilance: Betamimetic drug exposure in pregnancy enhances cardiovascular disease risk of offspring",

abstract = "The circadian amplitude of neonatal blood pressure, monitored for 2 days at 30-minute intervals during the first week of life on 39 babies exposed in utero to betamimetics, was statistically significantly larger than that of the 126 unexposed babies. The respective circadian double amplitudes (± SEM) were 7.9 ± 0.8 vs. 5.6 ± 0.3 mm Hg for systolic blood pressure (P=0.005) and 5.7 ± 0.6 vs. 4.0 ± 0.2 mm Hg for diastolic blood pressure (P = 0.020). An above-threshold circadian amplitude of blood pressure being associated with an increased cardiovascular disease risk, the results, corroborated independently during adolescence, warrant caution in prescribing betamimetics to prevent premature labor.",

keywords = "Betamimetics, Blood pressure, Cardiovascular disease risk, Circadian amplitude, Neonate, Offspring, Pregnancy, Premature labor",

author = "Cristina Maggioni and Cornelissen-Guillaume, {Germaine G} and Syutkina, {Elena V.} and Johnson, {Dana E} and Franz Halberg",

year = "2003",

language = "English (US)",

volume = "24",

pages = "102--104",

journal = "Neuroendocrinology Letters",

issn = "0172-780X",

publisher = "Maghira and Maas Publications",

number = "SUPPL. 1",

}

TY - JOUR

T1 - Pharmacovigilance

T2 - Betamimetic drug exposure in pregnancy enhances cardiovascular disease risk of offspring

AU - Maggioni, Cristina

AU - Cornelissen-Guillaume, Germaine G

AU - Syutkina, Elena V.

AU - Johnson, Dana E

AU - Halberg, Franz

PY - 2003

Y1 - 2003

N2 - The circadian amplitude of neonatal blood pressure, monitored for 2 days at 30-minute intervals during the first week of life on 39 babies exposed in utero to betamimetics, was statistically significantly larger than that of the 126 unexposed babies. The respective circadian double amplitudes (± SEM) were 7.9 ± 0.8 vs. 5.6 ± 0.3 mm Hg for systolic blood pressure (P=0.005) and 5.7 ± 0.6 vs. 4.0 ± 0.2 mm Hg for diastolic blood pressure (P = 0.020). An above-threshold circadian amplitude of blood pressure being associated with an increased cardiovascular disease risk, the results, corroborated independently during adolescence, warrant caution in prescribing betamimetics to prevent premature labor.

AB - The circadian amplitude of neonatal blood pressure, monitored for 2 days at 30-minute intervals during the first week of life on 39 babies exposed in utero to betamimetics, was statistically significantly larger than that of the 126 unexposed babies. The respective circadian double amplitudes (± SEM) were 7.9 ± 0.8 vs. 5.6 ± 0.3 mm Hg for systolic blood pressure (P=0.005) and 5.7 ± 0.6 vs. 4.0 ± 0.2 mm Hg for diastolic blood pressure (P = 0.020). An above-threshold circadian amplitude of blood pressure being associated with an increased cardiovascular disease risk, the results, corroborated independently during adolescence, warrant caution in prescribing betamimetics to prevent premature labor.

KW - Betamimetics

KW - Blood pressure

KW - Cardiovascular disease risk

KW - Circadian amplitude

KW - Neonate

KW - Offspring

KW - Pregnancy

KW - Premature labor

UR - http://www.scopus.com/inward/record.url?scp=0242493468&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0242493468&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0242493468

SN - 0172-780X

VL - 24

SP - 102

EP - 104

JO - Neuroendocrinology Letters

JF - Neuroendocrinology Letters

IS - SUPPL. 1

ER -

Pharmacovigilance: Betamimetic drug exposure in pregnancy enhances cardiovascular disease risk of offspring

Abstract

Keywords

UN SDGs

OpenUrl availability

Other files and links

Fingerprint

Cite this